Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study
Schlenk, R. F.; Paschka, P.; Krzykalla, J.; Weber, D.; Kapp-Schwoerer, S.; Gaidzik, V. I. & Leis, C. et al. (2018)
Blood, 132(Supplement 1) pp. 81-81. DOI: https://doi.org/10.1182/blood-2018-99-113442
Documents & Media
Details
- Authors
- Schlenk, Richard F.; Paschka, Peter; Krzykalla, Julia; Weber, Daniela; Kapp-Schwoerer, Silke; Gaidzik, Verena I.; Leis, Claudia; Fiedler, Walter; Kindler, Thomas; Schroeder, Thomas; Mayer, Karin; Lübbert, Michael; Wattad, Mohammed Amen; Götze, Katharina S.; Horst, Heinz A.; Koller, Elisabeth; Wulf, Gerald ; Schleicher, Jan; Bentz, Martin; Greil, Richard; Hertenstein, Bernd; Krauter, Jürgen; Martens, Uwe; Nachbaur, David; Samra, Maisun Abu; Girschikofsky, Michael; Benner, Axel; Thol, Felicitas; Heuser, Michael; Ganser, Arnold; Döhner, Konstanze; Döhner, Hartmut
- Issue Date
- 2018
- Journal
- Blood
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
